Kura spins out Caspian to test menin

Kura Oncology has formed a new biotechnology company, Caspian Therapeutics, to develop medicines known as menin inhibitors for diabetes and other cardiometabolic conditions. The startup has secured $50 million in financing from investors including Eli Lilly, BVF Partners, the T1D Fund, and Kura itself, which will retain an approximate 50% stake in the new firm.

A New Home for a Diabetes Drug

The spinout was created to house a drug candidate codenamed KO 7246, which Kura had been exploring outside its core cancer focus. Kura Chief Executive Officer and Caspian executive chairman Troy Wilson explained the move, stating, "As a company at our size and stage, you cannot be all things to all people." He added that the project required dedicated expertise and capital to progress. Caspian can operate with a smaller budget than typical biotech startups because it shares operational teams with its parent company, Kura.

From Leukemia to Beta Cells

Menin inhibitors are a proven approach in blood cancer. By blocking the menin protein's interaction with another called KMT2A, these drugs prevent the rapid reproduction of leukemia cells. Two such therapies are already approved in the U.S. For acute myeloid leukemia: Syndax Pharmaceuticals' Revuforj and Kura's own Komzifti, co-developed with Kyowa Kirin. Kura's leukemia drug generated nearly $15 million in sales in the first half of 2026.

In diabetes, the mechanism aims at regeneration. Blocking menin can "take the brakes off pancreatic beta islet cells," according to Wilson, which is necessary for restoring normal glucose and insulin production. Preclinical testing of KO 7246 suggests the treatment might help the body regenerate these key beta cells. The drug is being investigated for both Type 1 and Type 2 diabetes.

Competitive Landscape and Safety Profile

Caspian faces one direct competitor in Biomea Fusion, which has a menin inhibitor already in mid-stage clinical testing. Wilson acknowledged that Biomea "has a time advantage," but contended that Caspian's drug could have a superior safety profile. Key preclinical research indicates Caspian's compound does not appear to spur abnormal growth in other cell types. The company plans to present additional data at a medical meeting later this month but has not disclosed a timeline for beginning human trials.

Combination Potential and Analyst View

The startup is also exploring the potential of using its menin inhibitors alongside popular GLP-1 drugs to help patients whose diabetes is not controlled by existing treatments. "Once you have a drug that has good safety and clinical activity, give it to talented scientists and clinicians, and they'll help you learn how to use it," Wilson said.

Following the announcement, Kura's stock price dipped slightly. However, TD Cowen analyst Phil Nadeau wrote in a client note that the spinout appeared to "offer shareholders opportunity for upside while reducing the downside risk." He stated the deal enables the "efficient development of KO 7246 while Kura’s resources remain focused on oncology."